Agios Pharmaceuticals
AGIO
174 hedge funds and large institutions have $3.37B invested in Agios Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 59 increasing their positions, 68 reducing their positions, and 42 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
47% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $23M
20% more capital invested
Capital invested by funds: $2.82B → $3.37B (+$549M)
0.07% less ownership
Funds ownership: 93.83% → 93.76% (-0.07%)
13% less funds holding
Funds holding: 200 → 174 (-26)
13% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 68
60% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 42
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$175M |
| 2 |
JP Morgan Chase
New York
|
+$63.4M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$44.1M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$40.8M |
| 5 |
HM
HealthCor Management
New York
|
+$26.5M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$95.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$50.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$44.1M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$27.4M |
| 5 |
Goldman Sachs
New York
|
-$25.8M |
AGIO Hedge Fund Activity: Q1 2021 in Review
174 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2021, worth a combined $3.37B — up 20% from $2.82B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of AGIO and 17 opened new positions — a net loss of 25 holders — while 68 trimmed existing stakes and 59 added.
The largest buyer was Fidelity Investments, adding an estimated $175M. The largest seller was OrbiMed, exiting entirely with an estimated $95.6M sold.
- 174 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2021, down from 200 in Q4 2020.
- Funds reported $3.37B of Agios Pharmaceuticals stock for Q1 2021, up 20% quarter-over-quarter.
- 17 funds opened new Agios Pharmaceuticals positions in Q1 2021 and 42 closed out, a net change of -25 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $175M added.
- The largest Agios Pharmaceuticals seller in Q1 2021 was OrbiMed, an estimated $95.6M sold.
Based on aggregated 13F filings for Q1 2021.